Carna Biosciences Inc. (JASDAQ: 4572), a biopharmaceutical company focusing on the discovery and development of innovative small molecule drugs, today announced that it has entered into a license agreement with BioNova Pharmaceuticals Limited, a China-based biopharmaceutical company focused on the development and commercialization of innovative medicines for the treatment of diseases with high unmet medical needs, to develop and commercialize AS-1763, a novel next-generation non-covalent Bruton’s tyrosine kinase (BTK) inhibitor for the Greater China territory.
Carna Biosciences Inc. (JASDAQ: 4572), a biopharmaceutical company focusing on the discovery and development of innovative small molecule drugs, today announced that it has entered into a license agreement with BioNova Pharmaceuticals Limited, a China-based biopharmaceutical company focused on the development and commercialization of innovative medicines for the treatment of diseases with high unmet medical needs, to develop and commercialize AS-1763, a novel next-generation non-covalent Bruton’s tyrosine kinase (BTK) inhibitor for the Greater China territory.
最後に買って正解かな。